Next week, Lieff Cabraser partners Lexi J. Hazam and Michael Levin-Gesundheit will be panelists at the 62nd Annual Consumer Attorneys of California Convention, being held from November 16-19, 2023, at the Palace Hotel in San Francisco.
On day two of the convention (11/17), Lexi will discuss “Mass Torts & Class Actions,” and on day three (11/18), Michael will discuss “Emerging Torts.”
Other event topics include: “Artificial Intelligence: The Reality of AI,” “Sexual Abuse Cases – Schools, Sports, Scouts and Sunday Schools,” “DEI: Trauma Informed Leadership,” among others.
For more information and to register to attend, visit the CAOC convention website.
About Lexi J. Hazam
A leader within the plaintiffs’ bar, Lexi J. Hazam chairs the firm’s Personal Injury and Mass Tort practice group and represents clients in mass torts cases and qui tam actions, as well as complex class actions. In addition to her leadership roles in the Teen/Youth Social Media Injuries litigation and the Abilify Gambling Injuries MDL litigation, she also served on the Plaintiffs’ Steering Committee and as Co-Chair of the Plaintiffs’ Science and Experts Committee in the nationwide Benicar side effect injuries litigation. Lexi has spoken at numerous conferences on these and other drug injury cases, as well as on multiple recent California wildfire injury cases.
In 2016, Lexi was elected as Chair Elect of the American Association for Justice’s Section on Toxic, Environmental, and Pharmaceutical Torts (STEP) after previously serving as vice-chair. In 2018, Lexi was elected as Vice-Chair of the American Association for Justice’s Section on Qui Tam Litigation after previously serving as Co-Secretary.
About Michael Levin-Gesundheit
A partner in Lieff Cabraser’s San Francisco office, Michael Levin-Gesundheit is dedicated to seeking fairness for government entities, employees, consumers, and injury victims, regardless of the resources of the defendant. Michael served on the San Francisco opioid bellwether team, working to obtain evidence and on the 2022 trial, where he developed multiple trial witnesses. His focus, in San Francisco and across other opioid cases in the multidistrict litigation, was Walgreens, for its role in preventing and discouraging its pharmacists from conducting the prescription due diligence required under the Controlled Substances Act. Walgreens ultimately settled with San Francisco for $229.6 million to avoid a second-phase abatement trial.
Other corporations Michael has taken on include Goldman Sachs and Microsoft for gender discrimination, Google for invasions of privacy, a major pharmaceutical company for fraudulent marketing practices, and an international consultancy for mistreatment of H-1B visa workers.